Form 4: Acrivon Therapeutics Chief Legal Officer Acquires Stock Options
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, acquired stock options for 93,693 shares of common stock on March 1, 2025.
Summary
- On March 1, 2025, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., acquired stock options for 93,693 shares of the company's common stock.
- The exercise price of these options is $5.31 per share.
- 25% of the options will vest on March 1, 2026, with the remaining options vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
- The options expire on February 28, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It is common for companies to grant stock options to executives as part of their compensation packages.
Stakeholder Impact
- The granting of stock options aligns the interests of the Chief Legal Officer with those of the shareholders, incentivizing her to contribute to the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of the stock option grant. |
| 03/01/2026 | Date when 25% of the stock options vest. |
| 02/28/2035 | Expiration date of the stock options. |
| 03/04/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.